Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in bipolar disorder

Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230814059145N1

Enrollment

Registered

2023-10-22

Start date

2023-11-01

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder. Bipolar disorder

Interventions

Intervention 1: Intervention group:The intervention group will receive quetiapine with the addition of sodium valproate and aripiprazole. Aripiprazole will be added to patients' current medications at

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18 to 60 years Confirmation of bipolar disorder based on DSM-5 criteria

Exclusion criteria

Exclusion criteria: Not having cardiovascular, respiratory, kidney or digestive diseases Not pregnant Not suffering from drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: Before the intervention and weeks 4, 8 and 12 after the intervention. Method of measurement: Hamilton.;Symptoms of mania. Timepoint: Before the intervention and weeks 4, 8 and 12 after the intervention. Method of measurement: Young mania rating scale.;Obsessive compulsive symptoms. Timepoint: Before the intervention and weeks 4, 8 and 12 after the intervention. Method of measurement: Yale brown obsessive compulsive scale scoring.	—

Measure

Time frame

Depression. Timepoint: Before the intervention and weeks 4, 8 and 12 after the intervention. Method of measurement: Hamilton.;Symptoms of mania. Timepoint: Before the intervention and weeks 4, 8 and 12 after the intervention. Method of measurement: Young mania rating scale.;Obsessive compulsive symptoms. Timepoint: Before the intervention and weeks 4, 8 and 12 after the intervention. Method of measurement: Yale brown obsessive compulsive scale scoring.

—

Secondary

Measure	Time frame
Drug complication. Timepoint: Before the intervention and weeks 4, 8 and 12 after the intervention. Method of measurement: Abnormal Involuntary Movement scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Poorshams

Ahvaz University of Medical Sciences

poorshams@ajums.ac.ir+98 61 3374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026